DFX Intelligence
Data Factory
Reading the graph
Reading the graph
Venture Capital
Boston, MA
Aiming to overcome technical and funding barriers in antibiotic development and ensuring a sustainable pipeline of new antibiotics to fight superbugs.
Data as of (this record's last observation) from federal regulator filings, firm and issuer disclosures. Page built and rebuilt at most every 15 minutes.
| Fund | Vintage | Lifecycle | Form D sold | GAV | LPs |
|---|---|---|---|---|---|
| AMR Action Fund L.P. | n/a | Unknown | $0 | $725M | 0 |
| AMR Action Fund, Scsp | n/a | Unknown | $0 | $252M | 0 |
| Company | State | Stage | Round size | Partner | Attribution | Observed |
|---|---|---|---|---|---|---|
| Vedanta Biosciences, Inc. | Ma | n/a | n/a | Martin Heidecker | Strongly supported | Aug 5, 2024 |
| Elion Therapeutics, Inc. | NY | n/a | n/a | Martin Heidecker | Strongly supported | Jun 26, 2024 |
Also named here, with no published line of their own (reach them through the firm): Martin Heidecker (Chief Investment Officer), Corinna Ruppli (Office Manager), Isabella Santi (Venture Associate), Henni-Karoliina Ropponen (Venture Associate), Junjun Gao (Principal), Carly Levine (Senior Associate), Dorothy Maloney (Compliance Officer), John Vancura (Chief Financial Officer), David Hellmuth (Chief Legal Officer, Chief Compliance Officer, Chief Operating Officer), David Hellmuth (Chief Legal Officer, Chief Compliance Officer, Chief Operating Officer), John William Vancura (Chief Financial Officer), David Christopher Hellmuth (Chief Compliance Officer, General Counsel And Chief Operating Officer).
Who to call is the organisation, the person's role and the line they published themselves: a business phone, office address, website or profile link from Form ADV, Form 13F or their own website, with that source named on every value. The counts above are what a reveal returns; a personal email is rarely published, so most reveals are the firm's line. Never data bought from a provider, never anything personal. Reveals by plan